Interaction between oncodrivers and immune response has been documented in HER2+ BC, where trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) by facilitating cross-link between tumor antigen with its antigen-binding fragment and recruitment of effector cells by interaction with the Fc region (fragment crystallizable region), resulting in cytokine release and cytotoxic cell death (156). This evidence concerns the gene ERBB2 and neoplasm.